A full course of BV treatment
in one oral dose1

Solosec® (secnidazole) is the first and only antibiotic treatment for bacterial vaginosis (BV) designed to deliver a complete course of therapy in just one oral dose1,2

Solosec is designed to deliver a complete course of therapy for BV (bacterial vaginosis) in just one oral dose.

Treatment completion can be challenging to your BV patients for many reasons.2-4

Solosec offers them an easy one-dose oral treatment option that may potentially improve adherence.5

Even though BV is common, treatment can be challenging. Find out why.2-4

Explore BV Challenges

Solosec was proven to be effective in pivotal trials.1,6,7

View Efficacy Trials

Learn how Solosec delivers potent antimicrobial activity in a single dose.1,5

See Pharmacokinetic Properties

Solosec is easy to take—a full course of treatment in one oral dose.1,8

Dosing Explained


Get more information about how single-dose Solosec can help your patients.1

Learn More


  1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2017.
  2. Broumas AG, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. Adv Ther. 2000;17(3):159-166.
  3. Centers for Disease Control and Prevention. Sexually transmitted diseases: treatment guidelines, 2015. Morbid Mortal Wkly Rep (MMWR). 2015;64(3):1-140.
  4. Data on File, Patient Research. Symbiomix, a Lupin Company. 2013.
  5. Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018; 13:507-524. doi: 10.2217/fmb-2017-0270.
  6. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1-678.e9. doi: 10.1016/j.ajog.2017.08.017.
  7. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2017;130(2):379-386.
  8. Data on File, Physician Research. Advantage Healthcare, Inc. Prepared December 23, 2014.